Drug intelligence / Profile preview

SFT-601

Development stage: Preclinical
Lead developer: invoX Pharma
Modality: Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules
Administration: Inhalation

Overview

SFT-601 is an investigational inhaled drug formulation being developed by invoX Pharma for the treatment of chronic obstructive pulmonary disease (COPD). The therapy is designed for delivery via the Softhaler® platform, a proprietary propellant-free, multi-dose dry powder inhaler (DPI) technology intended to optimize pulmonary drug deposition and patient ease of use. As of early 2024, SFT-601 is in the early stages of development (preclinical or early clinical), and its specific active pharmaceutical ingredient and molecular mechanism of action have not been publicly disclosed by the developer.

Other names: SFT-601-IVOXSFT601-IVOXSFT 601-IVOX

Beyond the preview

Go deeper on SFT-601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SFT-601.

Explore the full profile